← Leaderboards
Michele M Sale
Wake Forest University Health Sciences
$7,089,664
Attributed
$8,164,081
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–18$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$8,164,081 · 5
By mechanism
R01$5,726,734 · 2
U01$1,884,098 · 1
M01$288,512 · 1
R21$264,737 · 1
Top collaborators
- Bradford B Worrall5 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Keith L Keene$1,520,920
- Edward Hal Kincaid$3,625,399
- Sudarshan Krishnamurthy$108,512
- James F Toole$17,998,584
- David P Friedman$11,550,253
Others in their field
Top investigators on “Genotype”
- David R. Weir · University Of Michigan At Ann Arbor$303,033,420
- Richard A Gibbs · Baylor College Of Medicine$211,329,145
- Constance Ann Benson · University Of California, San Diego$187,132,366
- Stacey Gabriel · Massachusetts Institute Of Technology$153,486,482
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$141,132,078
Research focus
GenotypeResearch PersonnelResourcesInnovationRisk FactorsAccountingUniversitiesStrokeGenomicsFollow-UpSamplingGeneticCollaborationsGenetic Predisposition To DiseaseGenetic Risk FactorGenetic MaterialsGenetic VariantNational Human Genome Research InstituteBaseFacilities And Administrative CostsGenome Wide Association StudyDietGenesDirect Costs
Grant awards (13)
Gastrointestinal Microbiome and Stroke Outcomes Network (GEMSTONE)$264,737
R21 · FY2018 · NS
Pharmacogenomic studies in VISP: results & implications for clinical trial design$698,373
U01 · FY2011 · HG · contact PI
Pharmacogenomic studies in VISP: results & implications for clinical trial design$146,300
U01 · FY2011 · HG · contact PI
Genetic contributors to diabetes and dyslipidemia in African Americans$1,245,341
R01 · FY2010 · DK · contact PI
Pharmacogenomic studies in VISP: results & implications for clinical trial design$614,434
U01 · FY2010 · HG · contact PI
Genetic contributors to diabetes and dyslipidemia in African Americans$143,505
R01 · FY2010 · DK · contact PI
Genetic contributors to diabetes and dyslipidemia in African Americans$3,008,855
R01 · FY2009 · DK · contact PI
Pharmacogenomic studies in VISP: results & implications for clinical trial design$424,991
U01 · FY2009 · HG · contact PI
GENETICS OF AFRICAN AMERICAN TYPE 2 DIABETES$288,512
M01 · FY2006 · RR · contact PI
Genetics of African American type 2 diabetes$494,484
R01 · FY2005 · DK
Genetics of African American type 2 diabetes$29,189
R01 · FY2005 · DK
Genetics of African American type 2 diabetes$442,204
R01 · FY2004 · DK
Genetics of African American type 2 diabetes$363,156
R01 · FY2003 · DK